Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer: a case of localised urticarial vasculitis following anastrozole therapy and a review of the literature.

Bock VL, Friedlander M, Waring D, Kossard S, Wood GK.

Australas J Dermatol. 2014 Nov;55(4):282-5. doi: 10.1111/ajd.12110. Epub 2013 Dec 2.

PMID:
24575835
2.
3.

Hormonal therapies for early breast cancer: systematic review and economic evaluation.

Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.

Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134. Review.

4.

Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: Case report and review of the literature.

Lycette JL, Luoh SW, Beer TM, Deloughery TG.

Breast Cancer Res Treat. 2006 Oct;99(3):249-55. Epub 2006 Jun 3. Review.

PMID:
16752073
6.

Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer.

Sanford M, Plosker GL.

Drugs. 2008;68(9):1319-40. Review.

PMID:
18547136
7.
8.

Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.

Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch C, Stierer M, Hofbauer F, Renner K, Dadak C, Rücklinger E, Samonigg H; Austrian Breast and Colorectal Cancer Study Group.

J Natl Cancer Inst. 2007 Dec 19;99(24):1845-53. Epub 2007 Dec 11. Erratum in: J Natl Cancer Inst. 2008 Feb 6;100(3):226.

9.
10.

The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.

Mouridsen HT, Robert NJ.

Eur J Cancer. 2005 Aug;41(12):1678-89. Epub 2004 Nov 25. Review.

PMID:
16098456
11.

Focus on anastrozole and breast cancer.

Mokbel K.

Curr Med Res Opin. 2003;19(8):683-8. Review.

PMID:
14687437
13.

Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.

Eisen A, Trudeau M, Shelley W, Messersmith H, Pritchard KI.

Cancer Treat Rev. 2008 Apr;34(2):157-74. doi: 10.1016/j.ctrv.2007.11.001. Epub 2007 Dec 31. Review.

PMID:
18164821
14.

Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.

Carlson RW, Henderson IC.

Breast Cancer Res Treat. 2003;80 Suppl 1:S19-26; discussion S27-8. Review.

PMID:
14535531
15.

The role of aromatase inhibitors in early breast cancer.

Chung CT, Carlson RW.

Curr Treat Options Oncol. 2003 Apr;4(2):133-40. Review.

PMID:
12594939
16.

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T; ATAC Trialists' Group.

Lancet. 2002 Jun 22;359(9324):2131-9. Erratum in: Lancet 2002 Nov 9;360(9344):1520.

PMID:
12090977
17.
18.

Drug-induced pruritic micropapular eruption: anastrozole, a commonly used aromatase inhibitor.

Bremec T, Demsar J, Luzar B, Pavlović MD.

Dermatol Online J. 2009 Jul 15;15(7):14.

19.

Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition.

Spicer J, Ellis P.

Cancer Lett. 2007 Apr 18;248(2):165-74. Epub 2006 Aug 21. Review.

PMID:
16919870
20.

Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial.

Buzdar A.

Clin Breast Cancer. 2003 Apr;4 Suppl 1:S42-8. Review.

PMID:
12756078
Items per page

Supplemental Content

Write to the Help Desk